Institutions which provide medical or health-related services.
Extended care facilities which provide skilled nursing care or rehabilitation services for inpatients on a daily basis.
Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior.
Long-term care facilities which provide supervision and assistance in activities of daily living with medical and nursing services when required.
Tumors or cancer of the PROSTATE.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the human BREAST.
Tumors or cancer of the LUNG.
Tumors or cancer of the STOMACH.
Tumors or cancer of the COLON.
Those facilities which administer health services to individuals who do not require hospitalization or institutionalization.
Architecture, exterior and interior design, and construction of facilities other than hospitals, e.g., dental schools, medical schools, ambulatory care clinics, and specified units of health care facilities. The concept also includes architecture, design, and construction of specialized contained, controlled, or closed research environments including those of space labs and stations.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
A housing and health care alternative combining independence with personal care. It provides a combination of housing, personalized supportive services and health care designed to meet the needs, both scheduled and unscheduled, of those who need help with activities of daily living. (www.alfa.org)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
Management of the organization of HEALTH FACILITIES.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Health care institutions operated by private groups or corporations for a profit.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the UTERINE CERVIX.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
An area of recreation or hygiene for use by the public.
Areawide planning for health care institutions on the basis of projected consumer need.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Formal voluntary or governmental procedures and standards required of hospitals and health or other facilities to improve operating efficiency, and for the protection of the consumer.
The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
Tumors or cancer of the URINARY BLADDER.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.
Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
A cell line derived from cultured tumor cells.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.
The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
Tumors or cancer of the RECTUM.
Facilities which provide nursing supervision and limited medical care to persons who do not require hospitalization.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
DNA present in neoplastic tissue.
Radiographic examination of the breast.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
Inhaling and exhaling the smoke of burning TOBACCO.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor.
Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor.
The degree to which individuals are inhibited or facilitated in their ability to gain entry to and to receive care and services from the health care system. Factors influencing this ability include geographic, architectural, transportational, and financial considerations, among others.
The clear, watery fluid which fills the anterior and posterior chambers of the eye. It has a refractive index lower than the crystalline lens, which it surrounds, and is involved in the metabolism of the cornea and the crystalline lens. (Cline et al., Dictionary of Visual Science, 4th ed, p319)
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
A subspecialty of internal medicine concerned with the study of neoplasms.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Facilities provided for human excretion, often with accompanying handwashing facilities.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
Tumors or cancer of the ESOPHAGUS.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Areas designated for use by the armed forces personnel.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
Transplantation between animals of different species.
Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Tumors or cancer of the LIVER.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A malignant epithelial tumor with a glandular organization.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Institutions specializing in the care of cancer patients.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Tumors or cancer of the MOUTH.
A range of values for a variable of interest, e.g., a rate, constructed so that this range has a specified probability of including the true value of the variable.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Geriatric long-term care facilities which provide supervision and assistance in activities of daily living with medical and nursing services when required.
Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
The exposure to potentially harmful chemical, physical, or biological agents that occurs as a result of one's occupation.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Processes required for CELL ENLARGEMENT and CELL PROLIFERATION.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
A voluntary organization concerned with the prevention and treatment of cancer through education and research.
Tumors or cancer located in bone tissue or specific BONES.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
A country spanning from central Asia to the Pacific Ocean.
A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A gene silencing phenomenon whereby specific dsRNAs (RNA, DOUBLE-STRANDED) trigger the degradation of homologous mRNA (RNA, MESSENGER). The specific dsRNAs are processed into SMALL INTERFERING RNA (siRNA) which serves as a guide for cleavage of the homologous mRNA in the RNA-INDUCED SILENCING COMPLEX. DNA METHYLATION may also be triggered during this process.
Antibodies produced by a single clone of cells.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
Interruption or suppression of the expression of a gene at transcriptional or translational levels.
Institutions which provide health-related care and services to individuals who do not require the degree of care which hospitals or skilled nursing facilities provide, but because of their physical or mental condition require care and services above the level of room and board.
Tumors or cancer of the SKIN.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Elements of limited time intervals, contributing to particular results or situations.
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).
A porelike structure surrounding the entire circumference of the anterior chamber through which aqueous humor circulates to the canal of Schlemm.
Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Genes whose abnormal expression, or MUTATION are associated with the development, growth, or progression of NEOPLASMS.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Regular course of eating and drinking adopted by a person or animal.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
The frequency of different ages or age groups in a given population. The distribution may refer to either how many or what proportion of the group. The population is usually patients with a specific disease but the concept is not restricted to humans and is not restricted to medicine.
Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)
Antimetabolites that are useful in cancer chemotherapy.
The levels of excellence which characterize the health service or health care provided based on accepted standards of quality.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA.
The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
Social and economic factors that characterize the individual or group within the social structure.
Organized services to provide health care to expectant and nursing mothers.
Physical surroundings or conditions of a hospital or other health facility and influence of these factors on patients and staff.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Human COLORECTAL CARCINOMA cell line.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.)
Tumors or cancer of the THYROID GLAND.
RNA present in neoplastic tissue.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
Individuals whose ancestral origins are in the continent of Europe.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Diseases caused by factors involved in one's employment.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
The artificial induction of GENE SILENCING by the use of RNA INTERFERENCE to reduce the expression of a specific gene. It includes the use of DOUBLE-STRANDED RNA, such as SMALL INTERFERING RNA and RNA containing HAIRPIN LOOP SEQUENCE, and ANTI-SENSE OLIGONUCLEOTIDES.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.

Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. (1/430)

The purpose of this study was to review the progress in clinical and translational research in chronic myelogenous leukemia (CML) over the past 20 years at M.D. Anderson Cancer Center. The CML database updating the clinical and basic research investigations was reviewed as the source of this report. Publications resulting from these investigations were summarized. The long-term results with intensive chemotherapy, IFN-alpha therapy alone or in combination, autologous stem cell transplantation, and new agents such as homoharringtonine and decitabine showed encouraging results. Biological studies related to the BCR-ABL molecular abnormality, other molecular events, and the detection of minimal residual disease were detailed. Future strategies with potential promise in CML were outlined. Significant progress in understanding CML biology and in treating patients afflicted with the disease has occurred. Several therapeutic and research tools are currently investigated, which should hopefully improve further the prognosis of patients with CML.  (+info)

Initial experience with sentinel node biopsy in breast cancer at the National Cancer Center Hospital East. (2/430)

BACKGROUND: Axillary lymph node dissection is an important procedure in the surgical treatment of breast cancer. Axillary lymph node dissection is still performed in over half of breast cancer patients having histologically negative nodes, regardless of the morbidity in terms of axillary pain, numbness and lymphedema. The first regional lymph nodes draining a primary tumor are the sentinel lymph nodes. Sentinel node biopsy is a promising surgical technique for predicting histological findings in the remaining axillary lymph nodes, especially in patients with clinically node-negative breast cancer, and a worldwide feasibility study is currently in progress. METHODS: Intraoperative lymphatic mapping and sentinel node biopsy were performed in the axilla by subcutaneous injection of blue dye (indigocarmine) in 88 cases of stage 0-IIIB breast cancer. Sentinel lymph nodes were identified by detecting blue-staining lymph nodes or dye-filled lymphatic tracts after total or partial mastectomy. Finally, axillary lymph node dissection was performed up to Levels I and II or more. RESULTS: Sentinel lymph nodes were successfully identified in 65 of the 88 cases (74%). In the final histological examination, the sentinel lymph nodes in 40 cases were negative, including four cases with non-sentinel-node-positive breast cancer (specificity, 100%; sensitivity, 86%). In nine (31%) of the 29 cases with histologically node-positive breast cancer, the sentinel lymph nodes were the only lymph nodes affected. Axillary lymph node status was accurately predicted in 61 (94%) of the 65 cases. CONCLUSIONS: Although it was the initial experience at the National Cancer Center Hospital East, sentinel node biopsy proved feasible and successful. This method may be a reasonable alternative to the standard axillary lymph node dissection in patients with early breast cancer.  (+info)

Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. (3/430)

BACKGROUND: Because metastatic nonseminomatous germ cell cancer is a rare but treatable cancer, we have explored whether there is an association between the experience of the treating institution with this disease and the long-term clinical outcome of the patients, particularly patients with a poor prognosis. METHODS: We analyzed data on 380 patients treated in one of 49 institutions participating in the European Organization for Research and Treatment of Cancer/ Medical Research Council randomized trial of four cycles of bleomycin-etoposide-cisplatin followed by two cycles of etoposide-cisplatin versus three cycles of bleomycin-vincristine-cisplatin followed by three cycles of etoposide-ifosfamide-cisplatin-bleomycin, both treatment regimens given with or without filgrastim (granulocyte colony-stimulating factor). Institutions were divided into four groups based on the total number of patients entered in the trial. The groups were compared by use of the Cox proportional hazards model stratified for treatment with filgrastim and for patient prognosis as defined by the International Germ Cell Consensus Classification Group. With the use of this classification, only 65 % of the patients had a poor prognosis. RESULTS: Patients treated in the 26 institutions that entered fewer than five patients into the trial had an overall survival that was statistically significantly worse (two-sided P = .010; hazard ratio = 1.85; 95% confidence interval = 1.16-3.03) than that of patients treated in the 23 institutions that entered five patients or more. Overall survival and failure-free survival were similar among institutions that entered at least five patients. The observed effect may be related to differences in adherence to the chemotherapy protocol and in the frequency and extent of surgery for residual masses, although only the differences in dose intensity achieved statistical significance. CONCLUSIONS: Patients treated in institutions that entered fewer than five patients into the trial appeared to have poorer survival than those treated in institutions that entered a larger number of patients with "poor-prognosis" nonseminoma.  (+info)

Incremental costs of enrolling cancer patients in clinical trials: a population-based study. (4/430)

BACKGROUND: Payment for care provided as part of clinical research has become less predictable as a result of managed care. Because little is known at present about how entry into cancer trials affects the cost of care for cancer patients, we conducted a matched case-control comparison of the incremental medical costs attributable to participation in cancer treatment trials. METHODS: Case patients were residents of Olmsted County, MN, who entered phase II or phase III cancer treatment trials at the Mayo Clinic from 1988 through 1994. Control patients were patients who did not enter trials but who were eligible on the basis of tumor registry matching and medical record review. Sixty-one matched pairs were followed for up to 5 years after the date of trial entry for case patients or from an equivalent date for control patients. Hospital, physician, and ancillary service costs were estimated from a population-based cost database developed at the Mayo Clinic. RESULTS: Trial enrollees incurred modestly (no more than 10%) higher costs over various follow-up periods. The mean cumulative 5-year cost in 1995 inflation-adjusted U.S. dollars among trial enrollees after adjustment for censoring was $46424 compared with $44 133 for control patients. After 1 year, trial enrollee costs were $24645 compared with $23 964 for control patients. CONCLUSIONS: This study suggests that cancer chemotherapy trials may not imply budget-breaking costs. Cancer itself is a high-cost illness. Clinical protocols may add relatively little to that cost.  (+info)

Influence of data display formats on physician investigators' decisions to stop clinical trials: prospective trial with repeated measures. (5/430)

OBJECTIVE: To examine the effect of the method of data display on physician investigators' decisions to stop hypothetical clinical trials for an unplanned statistical analysis. DESIGN: Prospective, mixed model design with variables between subjects and within subjects (repeated measures). SETTING: Comprehensive cancer centre. PARTICIPANTS: 34 physicians, stratified by academic rank, who were conducting clinical trials. INTERVENTIONS: PARTICIPANTS were shown tables, pie charts, bar graphs, and icon displays containing hypothetical data from a clinical trial and were asked to decide whether to continue the trial or stop for an unplanned statistical analysis. MAIN OUTCOME MEASURE: Percentage of accurate decisions with each type of display. RESULTS: Accuracy of decisions was affected by the type of data display and positive or negative framing of the data. More correct decisions were made with icon displays than with tables, pie charts, and bar graphs (82% v 68%, 56%, and 43%, respectively; P=0.03) and when data were negatively framed rather than positively framed in tables (93% v 47%; P=0.004). CONCLUSIONS: Clinical investigators' decisions can be affected by factors unrelated to the actual data. In the design of clinical trials information systems, careful consideration should be given to the method by which data are framed and displayed in order to reduce the impact of these extraneous factors.  (+info)

An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. (6/430)

Ovarian cancer is the commonest cause of gynaecological cancer death in the UK, and guidelines for initial surgery and staging of this disease are widely available. We report a retrospective audit of the surgical management of patients with newly diagnosed ovarian cancer referred to the Christie Cancer Centre in Manchester in 1996. The aim was to assess compliance with surgical guidelines. The authors found that the majority of patients (92%) presented via an outpatient clinic and for these individuals surgery was therefore elective. This mode of presentation should allow management by a small number of dedicated gynaecologists at each hospital, but up to seven consultants in each hospital performed surgery on a relatively small number of patients. Furthermore, less than half the patients underwent the recommended surgical procedure. Although some patients may have 'inoperable' disease, these data suggest that a greater compliance with national and international guidelines are required to provide an optimal level of care.  (+info)

A comprehensive assessment of satisfaction with care: preliminary psychometric analysis in an oncology institute in Italy. (7/430)

BACKGROUND: Little is known about patients' perception of the quality of the care they receive in oncology hospitals. We developed a 61-item comprehensive assessment of satisfaction with care (CASC) to evaluate the competence of hospital physicians and nurses, as well as aspects of care organisation and hospital environment. The aims of this study were to define the structure of the CASC and assess the internal consistency and convergent and discriminant validity of its scales. PATIENTS AND METHODS: Three hundred ninety-five consecutive cancer patients discharged from an oncology institute in Italy were asked to complete the CASC at home and return it in a self-addressed envelope. RESULTS: Two percent of the patients refused to participate and 25% failed to return the questionnaire. Separate factor analyses of the CASC sub-scales disclosed the perceived extent of doctors' and nurses' availability, coordination, human quality, technical competence, provision of psychosocial care and information, as well as the patients' general satisfaction, perception of the organisation of their care, access and comfort. Multi-trait scaling analysis was carried out on item-grouping resulting from factor analyses. High levels of internal consistency and convergent validity were obtained but discriminant validity could be improved. CONCLUSIONS: Results of present psychometric testing of the CASC forecast adequate properties. This will be confirmed by repeating these analyses in a cross-cultural setting.  (+info)

Molecular characterization of a nosocomial outbreak of human respiratory syncytial virus on an adult leukemia/lymphoma ward. (8/430)

Although nosocomial transmission of human respiratory syncytial virus (HRSV) and its effect on morbidity and mortality among immunocompromised adults are well recognized, few studies have applied molecular techniques to differentiate nosocomial from community-acquired infections. Between January and April 1997, an outbreak of HRSV occurred among adult patients in a leukemia/lymphoma ward. Among 45 hospitalized patients undergoing bronchoscopy for investigation of acute respiratory illness, 8 were identified with HRSV infection. One infected patient developed symptoms before admission and was thought to be the index case. However, subsequent sequencing of 7 HRSV isolates identified 2 distinct genotypes, GA5 (1 case) and GB3 (6 cases). The 6 GB3 isolates could be further differentiated into 2 strains with identical nucleotide sequences that differed from each other and from 14 community HRSV isolates. Instead of a single nosocomial outbreak of HRSV, multiple introductions of HRSV likely occurred with distinct lines of nosocomial transmission.  (+info)

While he has put most of the fear and uncertainty behind him, Mike has not forgotten the compassion that kept him strong.. I think my wife and son really helped a lot, he says. My son is a kinesiology grad and very knowledgeable. He came along to every appointment and even gave the doctor a hard time.. He took such a thoughtful interest in my health. He lives in Calgary and we live in Canmore. He and his wife came out here and lived with us for a while. It means a lot. He just showed how much he cared and hes not a very vocal guy but his actions spoke a lot.. Mike has seen a lot of kindness from the tightknit staff at the Bow Valley Community Cancer Centre in Canmore where he has received a lot of his treatment and where he goes every two weeks for injections.. At the beginning of the COVID-19 pandemic, the volunteers at the Bow Valley Community Cancer Centre found new ways of offering patients something practical with a gesture of compassion and support. Instead of making quilts they ...
The UNM Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Comprehensive Cancer Center in the state.
The UNM Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Comprehensive Cancer Center in the state.
1 From Memorial Sloan Kettering Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; UCSF Helen Diller Family Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; Mayo Clinic Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Duke Cancer Institute; Consultant; Dana-Farber/Brigham and Womens Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; Vanderbilt-Ingram Cancer Center; UC San Diego Moores ...
The UNM Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Comprehensive Cancer Center in the state.
Fox Chase Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center research facility and hospital located in the Fox Chase section of Philadelphia, Pennsylvania, United States. The main facilities of the center are located on property adjoining Burholme Park. The center is part of the Temple University Health System (TUHS) and specializes in the treatment and prevention of cancer. The center was formed in 1974 by the merger of the American Oncologic Hospital, which was founded in 1904 as the first cancer hospital in the United States, and the Institute for Cancer Research, founded in 1927. The center was an independent, non-profit institution until it became part of TUHS July 1, 2012. Today it has almost 2,400 employees and an operating budget of $300 million. Research is conducted in more than 80 laboratories by a staff of more than 325 physicians and scientists who hold medical degrees, Ph.D.s or both. Fox Chases 100-bed hospital is one of the few facilities in the ...
WHO: Moffitt Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, will host Lymphoma Treatment Today and the Research Outlook for Tomorrow, a free educational event in collaboration with the Leukemia & Lymphoma Society®.. WHAT: The free educational event will feature Moffitt experts discussing the latest recommendations for treatment and promising research outlooks for Lymphoma. Attendees will have an opportunity ask questions during several breakout sessions.. WHEN: Thursday, Jan. 16, 2014, 4:30 - 8:30 p.m.. WHERE: Moffitt Cancer Center, 12902 Magnolia Drive, Stabile Research Building, Tampa, Fla. 33612. CONTACT: Pre-registration is required. Please call 813-963-6461, ext. 1798.. About Moffitt Cancer Center. Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitts excellence in research, its contributions to clinical trials, prevention and cancer ...
Birrer comes to UAB from Massachusetts General Hospital, where he is director of Medical Gynecologic Oncology and director of the Gynecologic Cancer Research Program at the Gillette Cancer Center. He also serves as the leader of the Dana Farber/Harvard Cancer Center program in gynecologic cancers and is a professor of medicine at Harvard Medical School.. Birrer will succeed Edward E. Partridge, M.D., the Evalina B. Spencer Chair in Oncology, who is retiring from UAB after a remarkable 48-year career, including 10 years as director of the Comprehensive Cancer Center. Birrer will join UAB on Aug. 1.. Mike Birrer is an outstanding physician-scientist who balances a vision of transformation and leadership, said Selwyn M. Vickers, M.D., FACS, senior vice president for Medicine and dean of the School of Medicine. He understands drivers for excellence in clinical care and has a vision for growing precision medicine in cancer care, as well as a well-established commitment to fundamental scientific ...
The Thoracic Surgery Department at Roswell Park Comprehensive Cancer Center offers a concentrated exposure to thoracic oncologic surgery at an NCI-designated comprehensive cancer center. The fellowship focuses on all aspects of thoracic oncology from diagnosis to staging to interdisciplinary treatment of lung cancer, esophageal cancer, chest wall masses, mediastinal masses and malignant pleural disease. On a routine basis, the post-AGCME clinical fellow is exposed to:
Get cancer facts, patient care numbers, updates on cancer clinical care, cancer support services, cancer research programs and learn about our community outreach efforts - as well as meet the U-M Comprehensive Cancer Center leadership.
Michelle M. Le Beau, PhD, Arthur and Marian Edelstein Professor of Medicine, was appointed director of the University of Chicago Medicine Comprehensive Cancer Center in April 2004. Dr. Le Beau is particularly well qualified to enhance translational and interdisciplinary research at the Comprehensive Cancer Center, in view of her impressive record of converting fundamental laboratory findings into highly relevant advances in the diagnosis and treatment of patients with hematological malignant diseases.. Dr. Le Beau received her PhD in pathology and genetics in 1981 at the University of Illinois. She subsequently obtained post-doctoral training at The University of Chicago Medicine under the mentorship of Janet D. Rowley, MD, DSc, the Blum-Riese Distinguished Service Professor of Medicine, and was appointed to the faculty in 1986, rising to tenured professor in 1997. In her capacity as director of the Cancer Cytogenetics Laboratory, Dr. Le Beau directs a cancer diagnostics laboratory, which ...
...UCSF Comprehensive Cancer Center basic scientists and clinical resear...The $11.9 million five-year grant with an additional $12 million in ...The so-called SPORE grant for Specialized Program of Research Excell... Our goal with this SPORE is to take a fresh approach to trying to so...,UCSF,Comprehensive,Cancer,Center,program,triumphs,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
Dr. Chiung-Yu Huang is Professor of Biostatistics at the Department of Epidemiology and Biostatistics and an elected Fellow of the American Statistical Association (ASA). She is a Member of the UCSF Helen Diller Family Comprehensive Cancer Center and an Adjunct Professor at the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center. She is recognized for her novel methodology research in survival analysis, competing risks analysis, recurrent event analysis, outcome-dependent sampling, and design and evaluation of vaccine efficacy trials. Dr. Huangs recent methodology contributions include (1) methods for combining information from external large databases, such as disease registries, to improve efficiency in the analysis of relatively small-scale studies that collect more detailed patient-level information. The importance of such methods has been recognized as we have now entered the big bata era; (2) methods to better model, estimate, and predict the risk of recurrent events to ...
Background: Vascular endothelial growth factor (VEGF) inhibitors disrupt angiogenesis and slow tumor growth but have a clinically significant side effect of hypertension. Between 9-59% of patients may develop hypertension induced VEGF inhibitors. Medication labeling for VEGF inhibitors recommend standard pharmacologic treatment of hypertension, interruption of chemotherapy, or discontinuation during hypertensive crisis. Actively controlling patients blood pressure allows them to receive the optimal dose of antineoplastic agent without the complication of hypertension. The purpose of this study is to evaluate an institutions practices of monitoring, identifying, and treating patients VEGF inhibitor induced hypertension. Methods: This retrospective, single-center, chart review assessed patients blood pressure measurements who received bevacizumab, ramucirumab, sorafenib, regorafenib, sunitinib, or pazopanib. Patients were excluded if they were less than 18, received VEGF inhibitors for ...
Men with advanced prostate cancer can now receive a new innovative treatment in the Sarah Bush Lincoln Regional Cancer Center. SBL is the only cancer center in the region to offer Xofigo® , a new type of targeted radiation therapy.. In May, the U.S. Food and Drug Administration (FDA) approved Xofigo® (radium 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones, but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.. Xofigo® is an important new treatment added to our robust nuclear therapeutics program, said Abdur R Shakir, MD, SBL Regional Cancer Center Medical Director. While we provide the people of East Central Illinois with leading-edge treatments for a broad range of cancers, we are proud to play a significant role in the development and delivery of important new breakthrough treatments as part of the Regional Cancer ...
DESCRIPTION (provided by applicant): The Robert H. Lurie Comprehensive Cancer Center of Northwestern University isan NCI-designated, university-based, matrix cancer center conducting a broadrange of multidisciplinary clinical, laboratory and population scienceresearch. The Cancer Center integrates the expertise and resources of theMedical School (Chicago Campus) and its five affiliated hospitals along withthose of departments located on the University?s Evanston Campus. Establishedin 1974, the Cancer Center functions as a full organizational unit with thestatus of a department of the Medical School. Since its inception, the CancerCenter has been dedicated to the process of discovery, advancing medicalknowledge and providing compassionate, state-of-the-art cancer care, asreflected in the following goals: 1. To conduct and support cancer researchand to integrate cancer-related research throughout the University 2. Tocoordinate and integrate cancer-related activities of the University ...
Recognizing a critical need to improve national vaccination rates for the human papillomavirus (HPV), the UAB Comprehensive Cancer Center has again united with each of the 69 National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention (CDC).. According to the CDC, incidence rates of HPV-associated cancers have continued to rise, with approximately 39,000 new HPV-associated cancers now diagnosed each year in the United States. Although HPV vaccines can prevent the majority of cervical, anal, oropharyngeal (middle throat) and other genital cancers, vaccination rates remain low across the U.S., with just 41.9 percent of girls and 28.1 percent of boys completing the recommend vaccine series.. The new guidelines from the CDC recommend that children aged 11 to 12 should receive two doses of the HPV vaccine at least six months apart. Adolescents and young adults older than 15 ...
Marnie Livingston, Tammy Welden and Abbey DeGraffenreid. Posted May 8, 2013. Marnie Livingston is grateful that her breast cancer was caught early and treated successfully. Tammy Welden is appreciative for her sons renewed health after an accident left him near death. Abbey DeGraffenreid is thankful that she no longer has signs of lymphoma. And Terri Wolf is glad for her secure job as an oncology nurse.. They are among a growing number of UC Davis Health System employees who invest in community health by supporting the UC Davis Comprehensive Cancer Center.. Livingston, an executive assistant, is donating $5,000 to the cancer centers expansion project to honor her surgical oncologist, James Goodnight.. I am donating because I want to make sure that other people can get the kind of care that I received, says Livingston.. Abbey DeGraffenreid, who works in perioperative services, is donating $5,000 to honor Goodnight, $2,500 to name an infusion chair and $2,500 to lymphoma research.. I hope to ...
A listing of the available patient education materials covering pancreatic cancer, pancreatic cysts and other diseases of the pancreas developed by the Pancreatic Cancer Clinic at the University of Michigan Comprehensive Cancer Center.
UNC Lineberger Comprehensive Cancer Centers leadership, program directors, communications and development staff, and N.C. Cancer Hospital administration
The Holden Comprehensive Cancer Center at the University of Iowa Hospitals & Clinics in Iowa City, Iowa is home to a lung cancer clinic where mesothelioma and other lung diseases are treated.
The UC Davis Comprehensive Cancer Center will host a Tweet chat to discuss the latest approaches to lung cancer treatment on Nov. 27 at 1 p.m. in recognition of Lung Cancer Awareness Month. Twitter users are invited to log in and join the conversation about new medical, surgical and radiation oncology approaches to the disease from cancer center experts. To join, follow #UCDcancerchat.
The mission of the Comprehensive Cancer Center is to elucidate the determinants of cancer, to develop cures for cancer and to prevent cancer through innovation and collaboration.. Members are expected to contribute to this overriding objective through a broad range of clinical and research activities including:. ...
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is an NCI-designated, university based, matrix cancer center conducting a broad range...
Case Western Reserve University Case Comprehensive Cancer Center is a top cancer clinic where leading mesothelioma doctors employ the latest treatment methods to help cancer patients.
The expansion of knowledge in the area of cancer biology which has taken place over the last 40 years has profoundly influenced clinical cancer research and made high-quality multidisciplinary cancer care imperative. In the United States, Comprehensive Cancer Centres (CCCs) have existed for a long time. To enhance their effectiveness and quality, the National Cancer Institute (NCI) has developed an accreditation methodology for CCCs [1]. NCI-designated CCCs are characterised by innovative high-quality cancer research covering the complete trajectory-from basic to clinical research, as well as dissemination of acquired knowledge.. ...
This training program is available to allied health care professionals and medical staff. It provides candidates with the appropriate training to fully operate a functional scientific oncology core facility at their home institution or hospital. The training will be provided at Roswell Park Comprehensive Cancer Center under the supervision of a core director and appropriate Roswell Park staff.
To advance knowledge, identify the most effective care and help future patients, the Edwards Comprehensive Cancer Center maintains an active clinical trials program and maintains a listing of the clinical trials that are currently available.. If you have questions about whether a clinical trial is an option for you, please contact Barbara Payne, RN, OCN, CCRP, Clinical Research Supervisor. For more information about Pediatric Clinical Trials, please contact Teresa Giles at 304.399.6653.. ...
UCLA scientists have unlocked an important mechanism that allows chemotherapy-carrying nanoparticles-extremely small objects between 1 and 100 nanometers (a billionth of a meter)-to directly access pancreatic cancer tumors, thereby improving the ability to kill cancer cells and hence leading to more effective treatment outcome of the disease. The researchers also confirmed the key role of a peptide (an extremely small protein) in regulating vascular access of the nanoparticle to the cancer site.. The discovery is the result of a two-year study co-led by Drs. Huan Meng and André Nel, members of UCLAs Jonsson Comprehensive Cancer Center and the UCLA California NanoSystems Institute. The findings are important as they demonstrate how the delivery of chemotherapy to pancreatic cancer can be improved significantly through the use of smart-designed nanoparticle features.. Pancreatic ductal adenocarcinoma is generally a fatal disease, with a five-year survival rate of less than 6 percent. The ...
CHAPEL HILL, N.C. - John Boggess, MD, associate professor of obstetrics and gynecology, was honored with a Health Care Heroes Award by the Triangle Business Journal. His Health Care Innovator/Researcher Award was given in recognition of his pioneering work with robotic surgery for gynecologic cancers. Boggess is a member of UNC Lineberger Comprehensive Cancer Center.. Due in large part to his training of other surgeons, robotic surgery is now the number one treatment for gynecologic cancer in the US, according to an executive with Intuitive Surgical, Inc. Boggess has presented the surgical techniques at national and international meetings and has hosted training visits to UNC for over 400 gynecologic oncology specialists.. The greatest significance of Boggess efforts is the impact robotic-assisted surgery has for patients. He has published reports in professional journals demonstrating that robotic-assisted surgery decreases complications, blood loss, pain and recovery time without compromising ...
The Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian / Columbia University Irving Medical Center is conducting hundreds of clinical trials to improve care for many types of conditions.. Use the tool below to find our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, links to the investigators biography, the trials eligibility criteria, and how to get more information.. ...
The Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian / Columbia University Irving Medical Center is conducting hundreds of clinical trials to improve care for many types of conditions.. Use the tool below to find our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, links to the investigators biography, the trials eligibility criteria, and how to get more information.. ...
Andrew SloanA new paper in the October issue of the journal Neurosurgical Focus finds the use of laser beneficial for the removal of large, inoperable glioblastoma (GBM) and other types of brain tumors. The paper is authored by Andrew Sloan, MD, and colleagues from University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine and Case Comprehensive Cancer Center (Wright J, et al. Neurosurg Focus. 2016 Oct; view video abstract).. Dr. Sloan and other investigators at the Case Comprehensive Cancer Center led the first in human trials, published in 2013, of a procedure with laser interstitial thermotherapy (LITT), a minimally invasive approach using a laser to cook a tumor through a tiny hole in the scalp and bone and the intra-operative MRI (iMRI) to fine tune the treatment rather than the surgeons direct vision.. However, one problem that he and other surgeons faced was tumor swelling. While LITT was successful for brain tumors smaller than the size of a ...
H. Lee Moffitt Cancer Center & Research Institute is a nonprofit cancer treatment and research center located in Tampa, Florida. Established in 1981 by the Florida Legislature, the hospital opened in October 1986, on the University of South Florida campus. Moffitt is the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida In 2017, U.S. News & World Report ranked Moffitt Cancer Center as the No. 9 cancer hospital in the nation. Funding for construction of the initial $70 million facility came primarily from the state of Floridas cigarette tax, while the momentum to create the center came from a cadre of legislators, physicians, educators, and business leaders who envisioned a new dimension of cancer care and research in Florida. In late 1978, H. Lee Moffitt, a Florida State Representative, recognized the need for a comprehensive cancer center within the state after several friends died from cancer. An excellent negotiator, Moffitt put his plan into motion by ...
The following piece was written by Dr. Susan A. Flocke, Director of the Behavioral Measurement Core Facility and co-Leader of the Cancer Prevention, Control and Population Research Program of the Case Comprehensive Cancer Center. She is also Associate Professor of Family Medicine and Epidemiology & Biostatistics at CWRU.. The Presidents Cancer Panel monitors progress of the National Cancer Program, identifies topics of high importance to the nation, and recommends action to address identified issues. Earlier this month, the Panel highlighted human papillomavirus (HPV) vaccines as an effective but under-used intervention to prevent cancers1.. Letters from the Panel were sent to multiple stakeholder organizations and to the President of the United States urging action to increase the uptake of HPV vaccination, especially in adolescents. The primary message of the calls to action is that HPV vaccination is cancer prevention and that the HPV vaccination is safe, effective, and especially important ...
The staff physicians attend outpatient services for thoracic diseases, and the department has approximately 60 beds in the hospital. Inpatient care is carried out by five teams. Each team consists of one staff physician and one or two residents and/ or trainee doctors. Protocol and case conferences are scheduled every Monday morning and afternoon, respectively. The journal club is scheduled on Thursday mornings.. A total of 413 new patients were admitted in 2015, and the backgrounds and initial treatments of these patients are shown in tables 1 and 2. The initial treatments were chemotherapy in 230, adjuvant chemotherapy after surgery in 44, chemoradiotherapy in 62, curative radiotherapy in 5, and supportive care including palliative radiotherapy in 49. Survival of lung cancer patients treated in 2006-2010 in our department is shown in Table 3.. ...
As a part of the National Cancer Institute-designated Case Comprehensive Cancer Center through Case Western Reserve University, UH Seidman Cancer Centers team of physician-scientists and clinical researchers are actively involved in more that 300 clinical trials that are studying and developing novel procedures, tests, tools and medications. Our physicians-scientists participate in trials using radiosurgery, photo dynamic therapy and minimally invasive surgery to advance local-regional therapies for cancer. Our leadership position in research provides direct benefits through new treatment options and improved quality of life. UH Seidman Cancer Center, part of the Case Comprehensive Cancer Center at Case Western Reserve University, is also one of seven cancer centers in the country to have access to a pipeline of new drugs through the National Cancer Institute, offering patients newer and better treatment options. We continue to participate in early development of FDA-approved drugs for all ...
UAB Comprehensive Cancer Center (41) cancer in the news (29) cancer (24) community support (23) uab (22) cancer research (21) research (15) cancer patients (12) why give wednesday (12) cancer screening (10) breast cancer (9) cancer funding (9) Breast Cancer Research Foundation of Alabama (7) skin cancer (7) women in medicine (7) american cancer society (6) anti-tobacco (6) young supporters board (6) cancer health disparities (5) clinical trials (5) lung cancer (5) spore grants (5) sunscreen (5) cancer and nutrition (4) childhood cancer (4) colorectal cancer (4) donate (4) oncology nurses (4) pancreatic cancer (4) young investigators (4) NCI designation (3) brain cancer (3) brain tumors (3) cancer drugs (3) childrens alabama (3) deep south network (3) early detection (3) guest blog (3) obesity (3) patient navigator (3) progress and promise (3) survivorship (3) university of alabama at birmingham (3) womens cancers (3) ArtBLINK Gala (2) Celebrating Life (2) National Cancer Institute (2) National ...
UAB Comprehensive Cancer Center (41) cancer in the news (29) cancer (24) community support (23) uab (22) cancer research (21) research (15) cancer patients (12) why give wednesday (12) cancer screening (10) breast cancer (9) cancer funding (9) Breast Cancer Research Foundation of Alabama (7) skin cancer (7) women in medicine (7) american cancer society (6) anti-tobacco (6) young supporters board (6) cancer health disparities (5) clinical trials (5) lung cancer (5) spore grants (5) sunscreen (5) cancer and nutrition (4) childhood cancer (4) colorectal cancer (4) donate (4) oncology nurses (4) pancreatic cancer (4) young investigators (4) NCI designation (3) brain cancer (3) brain tumors (3) cancer drugs (3) childrens alabama (3) deep south network (3) early detection (3) guest blog (3) obesity (3) patient navigator (3) progress and promise (3) survivorship (3) university of alabama at birmingham (3) womens cancers (3) ArtBLINK Gala (2) Celebrating Life (2) National Cancer Institute (2) National ...
Born in India, Daud spent his childhood in India and Dubai. He earned a medical degree in Nagpur, India, before coming to the United States in 1987 to pursue a research career.. Daud is now at UCSF, where he is a clinical professor in hematology/oncology and director of Melanoma Clinical Research at UCSFs Helen Diller Family Comprehensive Cancer Center. He combines patient care and research as he tries to better understand and develop new treatments for melanoma.. Dauds first stop in the U.S. was the Cleveland Clinic in Ohio, where he focused on molecular biology. He also met a young physician-researcher, Pamela Munster, whom he later married and who now also practices medicine at the Diller center. Her dedication and focus on caring for patients convinced Daud to balance his career between research and direct patient care.. From Cleveland he went to a medical residency at Indiana University Medical Center, where he developed his passion for oncology and working with cancer patients. I think ...
The University of Alabama at Birmingham Comprehensive Cancer Center, in collaboration with the University of Minnesota, has won an $11.5 million grant...
The University of Colorado Cancer Center is Colorados only National Cancer Institute-designated comprehensive cancer center -- one of only 41 in the nation.
The University of Colorado Cancer Center is Colorados only National Cancer Institute-designated comprehensive cancer center -- one of only 41 in the nation.
March 19, 2014 - Fort Washington, PA. FORT WASHINGTON, PA--(Marketwired - March 19, 2014) - On Friday, March 14, 2014, the National Comprehensive Cancer Network® (NCCN®) hosted its second roundtable of the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™, titled, The Affordable Care Act: Where are We Now? Clifford Goodman, PhD, The Lewin Group, moderated the discussion, which explored the Affordable Care Act (ACA) and health care reform in the United States, its effect on the oncology landscape, and assessment of risk for providers, payers, and patients.. Dr. Goodman was joined by Christian G. Downs, JD, MHA, Association of Community Cancer Centers; Liz Fowler, PhD, JD, Johnson & Johnson; Michael Kolodziej, MD, Aetna; Lee H. Newcomer, MD, MHA, UnitedHealthcare; John C. Winkelmann, MD, Oncology Hematology Care, Inc., and Councillor, American Society of Hematology; Mohammed S. Ogaily, MD, Henry Ford Health System; and W. Thomas Purcell, MD, MBA, University of Colorado Cancer ...
Cutaneous Oncology Center & Melanoma Program The Cutaneous Oncology Center is an interdisciplinary center staffed by faculty from dermatology, medical oncology, and surgical oncology. Under the direction of the Department of Dermatology and the Neag Comprehensive Cancer Center, our multidisc ...
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio States cancer program as exceptional, the highest rating given by NCI survey teams. As the cancer programs 228-bed adult patient-care component, The James is a Top Hospital as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S.News & World Report ...
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio States cancer program as exceptional, the highest rating given by NCI survey teams. As the cancer programs 228-bed adult patient-care component, The James is a Top Hospital as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report ...
As the Official Cancer Center of the State of New Mexico and as a National Cancer Institute-Designated Cancer Center (2P30CA118100-08), it is our mission and go...
Capital Regional Cancer Center also offers High-Dose Rate Brachytherapy (HDR) - an internal radiation therapy method that delivers a highly localized therapeutic dose of radiation directly to the tumor location. The radioactive source is applied using temporarily placed applicators. HDR involves a shortened treatment duration and is almost performed as an outpatient. As the therapy is extremely focused, the dose to surrounding organs and tissues is minimized, reducing potential side effects of treatment.. ...
UPMC Hillman Cancer Center, partner with University of Pittsburgh Cancer Institute (UPCI), is one of the nations largest integrated cancer care networks. Comprising 35 community cancer centers and 14 disease-specific specialty care centers, our network treats more than 36,000 new patients each year ...
Based on a study of nearly 2,000 breast cancer patients, researchers at the Swedish Cancer Institute in Seattle say that, in women between the ages of 40 and 49, breast cancers detected by mammography have a better prognosis. The study appears in the March issue of Radiology.. In our study, women aged 40 to 49 whose breast cancer was detected by mammography were easier to treat and had less recurring disease and mortality, because their cancer was found at an earlier stage, said Judith A. Malmgren, Ph.D., president of HealthStat Consulting, Inc.. Dr. Malmgren and a team of researchers reviewed breast cancer patient data from a dedicated registry at the Swedish Cancer Institutes community cancer center. The researchers analyzed data on 1,977 breast cancer patients between the ages of 40 and 49 who were treated between 1990 and 2008. The researchers looked at method of diagnosis (detected by mammography, patient or physician), stage at diagnosis (0-IV, confirmed by biopsy), treatment, and ...
Unfortunately, there is limited data on this patient population to help drive treatment options, Gharibo reflects. Proteasome inhibitors and chemotherapy can help achieve remission in a certain subset of patients for a short period of time. Usually we try to give chemotherapy, then perform an autologous transplant to optimize outcome. But given Cicons age and the fact that he was in good health prior to being diagnosed, Gharibo recommended a less common treatment regimen - an autologous transplant (in which a patients own peripheral blood stem cells are collected and reinfused in the body) followed by an allogeneic transplant, which utilizes stem cells or bone marrow from another donor. Time is of the essence, she says - noting the reason why this strategy is not widely pursued for plasma cell leukemia is that some patients dont have the advantage of being treated at a National Cancer Institute-designated Comprehensive Cancer Center like Rutgers Cancer Institute. It is beneficial for ...
TY - CHAP. T1 - Psychological distress, fatigue, burden of care, and quality of life in primary caregivers of patients with breast cancer undergoing autologous bone marrow transplantation.. AU - Gaston Johansson, Fannie. AU - Lachica, Evelyn M.. AU - Fall-Dickson, Jane M.. AU - Kennedy, M. John. PY - 2004/11. Y1 - 2004/11. N2 - PURPOSE/OBJECTIVES: To determine the effects of sociodemographic variables, psychological distress, fatigue, and quality of life (QOL) on burden of care in primary caregivers of patients with breast cancer undergoing autologous bone marrow transplantation (BMT). DESIGN: Descriptive, correlational, predictive. Setting: Urban National Cancer Institute-designated comprehensive cancer center in the eastern United States. SAMPLE: Convenience sample of 102 primary caregivers. METHODS: Participants completed the sociodemographic data form, Piper Fatigue Scale, Beck Depression Inventory, State-Trait Anxiety Inventory, QOL Index, and Measurement of Objective and Subjective Burden ...
Honorary Doctor of Science degrees have been awarded to Dr. Freeman from Albany Medical College, Niagara University, Adelphi University, and Catholic University of America. He was also awarded the University of California at San Francisco Medal. Other selected awards include: The Mary Lasker Award for Public Service; the Time, Inc. International Health and Medical Media Awards Lifetime Achievement Award; the American Cancer Societys Medal of Honor; the CDC Foundations Champion of Prevention Award; the Breast Cancer Research Foundations Jill Rose Award, the American Society of Clinical Oncologys Special Recognition Award; the Avon Breast Cancer National Leadership Award; the Susan G. Komen Breast Cancer National Foundations Betty Ford Award; the International Spirit of Life Foundation and the Washington Cancer Institutes Spirit of Life Award; the Mayo Clinic Charles G. Moertel Memorial Lectureship Award; the Association of Community Cancer Centers Achievement Award; the George ...
Cayuga Medical Center is a New York State Department of Health certified Stroke Center. We are designated as a Comprehensive Community Cancer Center by the National Cancer Institute. Our high-field Open MRI services are accredited by the American College of Radiology. We have received the prestigious Patient Safety Award from the NYS Department of Health. Our Radiation Medicine program is state-of-the-art and we are a premier affiliate of Roswell Park Cancer Institute. In short, we are delighted to be able to report that after decades of hard work and planning, medical and surgical services that residents once had to seek elsewhere are available right here in the community. ...
Christian G. Downs, JD, MHA, executive director of the Association of Community Cancer Centers (ACCC), discusses the upcoming 34th National Oncology Conference, taking place October 18 to 20 in Nashville, Tennessee.
Hemonc Today | The Association of Community Cancer Centers presented its Annual Achievement Award to Barbara McAneny, MD, FASCO, MACP.The ACCC Annual Achievement Award recognizes individuals who made outstanding contributions to cancer care and patients.
PHILADELPHIA (December 1, 2017) - Fox Chase Cancer Center is raising awareness on the risk factors for lung cancer. Lung cancer is the second most common cancer in both men and women, and the leading cause of cancer death, according to the American Cancer Society (ACS), and is by far the leading cause of cancer death.
Fox Chase Cancer Center - FACULTY POSITION IN IMMUNOLOGY - Philadelphia - The Fox Chase Cancer Center invites applicants for - Cell Career Network
Fox Chase Cancer Center doctors are not just clinical specialists-theyre also world-renowned cancer researchers. The results of studies conducted by Fox Chase doctors have been crucial in advancing our understanding of leukemia diagnosis and treatment around the world.
Lawrenceville, Ga.-Lawrenceville is proud to announce the opening of the Gwinnett Breast Center, designated as a Breast Center of Excellence. Combining state-of-the art screening, diagnostic services and a spa-like environment in one convenient location, the new center furthers patient ease and comfort.. GMC-Lawrenceville provides excellence in imaging services to thousands of women yearly, said Jay Dennard, chief operating officer, GMC-Lawrenceville. While patients overall satisfaction rate with breast health services grew from 95 percent to 100 percent from 2009 to 2010, the new Gwinnett Breast Center is critical in helping us continue this same trend.. Read more about the Gwinnett Breast Center opening.. ...
LOS ANGELES, Oct. 23 /PRNewswire/ -- USC/Norris Comprehensive Cancer Center announced that Judy and Larry Freeman have made a donation of $5 million to the USC/Norris Comprehensive Cancer Center, Keck School of Medicine of USC. The gift will designate the Judy and Larry Freeman Cancer Day Hospital, an outpatient facility currently located on the first floor of the USC/Norris Cancer Hospital. Larry Freeman is the founder of Freeman Cosmetics Corporation, which has long been a major supported of USCs Norris Cancer Center. Almost two decades ago they established the Freeman Aces Cancer Tennis Tournament, which has raised over $3 million. The Freemans decided to make this contribution as it is close to their hearts. The Freemans son, Mark, received care there as a young man. At the age of 22, a complaint of shoulder pain led to a diagnosis of t-cell lymphoma, a cancer that arises from lymphocytes, a type of white blood cells. Mark was successfully treated with nine months of chemotherapy. I have ...
Dr Ng is a Fellow at the Kids Cancer Centre, Sydney Childrens Hospital, Sydney, NSW. Dr Forsyth is a Registrar at the Kids Cancer Centre, Sydney Childrens Hospital. Dr Trahair is a Paediatric and Adolescent Oncologist at the at the Kids Cancer Centre, Sydney Childrens Hospital; and a Senior Lecturer at the School of Womens and Childrens Health, UNSW Sydney. Mr Carrington is the Youth Cancer Service Manager at the Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney. Dr Anazado is a Paediatric and Adolescent Oncologist at the Kids Cancer Centre, Sydney Childrens Hospital, and the Nelune Comprehensive Cancer Centre, Prince of Wales Hospital; and a Senior Lecturer at the School of Womens and Childrens Health, UNSW Sydney, Sydney, NSW ...
The symposium had two tracks, including a psychosocial track focused on information for patients, survivors and caregivers that delved into the psychosocial complexities of the AYA oncology population. The scientific track covered specific advances in targeted tumor-based therapy. Lectures by Dr. John Perentesis, Professor and Oncology Division Director at Cincinnati Childrens Hospital, and by Deborah Morosini, Vice President of Clinical Development at Foundation Medicine, highlighted advances in pharmacogenomics and how they are beginning to inform treatment modalities and clinical trials objectives for cancers common to AYA patients.. Lectures by Dr. Brandon Hayes-Latin, Director of the AYA Cancer Program at OHSU, and by Dr. Lindsay Frazier of the Dana Farber Cancer Institute shed light on how reorganization of the NCI infrastructure supporting the clinical trials process is enhancing collaborations between the Childrens Oncology Group and those cooperative groups developing clinical trials ...
Serving Fox Chase area and throughout Philadelphia Best Kids Dentist Contact : (215) 742-1200 .When you join the Prime Dentistry family, we will take care of you and your children through every milestone, understanding to keep your whole family smiling healthily and brightly. Best Kids Dentist Fox Chase Pa
"As demand for cancer care soars, OHSU expands Astoria facility". Portland Business Journal. Retrieved May 13, 2015. CS1 maint: ... In 2013, it opened an urgent care and primary care clinic in nearby Warrenton, Oregon. The hospital announced a new cancer ... Services at the facility include a level IV trauma center. Other services include hospice care, cardiac services, imaging, a ... CMH will also be opening a Seaside facility, which will include an urgent care and multi-specialty clinic, in January 2020. CMH ...
A cancer care centre was opened by Princess Alexandra in 2003. The old Bankend Road facility continues to be used as the ... at the High Dock facility in 1846. The High Dock facility has since been demolished. The hospital relocated to a new building ... The old Nithbank facility was subsequently used to accommodate the offices of NHS Dumfries and Galloway. The hospital moved ... The hospital has its origins in a small facility at Mill Hole in Burns Street in central Dumfries which opened as the Dumfries ...
The opposition subsided and a new Barts Heart Centre and new cancer care facilities were created. The Queen Mary Wing was ... A plan was formulated for Barts to develop as a centre of excellence in cardiac care and cancer. The plan came under threat ... Some facilities were saved, but the accident and emergency department closed in 1995, with facilities relocated to the Royal ... "Barts Cancer Research UK Centre". Archived from the original on 11 March 2014. Retrieved 11 March 2014. "When three hospital ...
Mercy Medical Center is an acute-care hospital, as opposed to a long-term or specialized facility. Despite this acute-care ... The facilities attempted to split service specialites in order to reduce costs. Mercy, for example, led local cancer treatment ... 2012: Mercy opened the Hall-Perrine Cancer Center, a four-story, 86,000-square-feet facility with 27 infusion chairs or beds ... Directive 58 says that Catholic health care facilities must generally provide artificial nutrition and hydration for patients ...
In 1932, Swedish opened the first cancer-care center west of the Mississippi. The board of trustees for Swedish Hospital were ... Nils August Johanson founded Swedish Hospital in 1910 as Seattle's first modern nonprofit medical facility. Dr. Johanson was an ... a network of more than 100 primary-care and specialty clinics. It is affiliated with many other health care providers across ... ambulatory care centers in the cities of Redmond and Mill Creek, and Swedish Medical Group, ...
The hospital now has a Centre for Home Based Palliative Care, mainly to serve cancer patients. The Centre is able to serve ... Elizabeth's Hospital, Hyderabad is a 100-bed health-care facility established in Pakistan in 1958. It serves the people of ... Not only is it a hospital but a facility for training nurses and midwives to guarantee the future for Pakistani women and ... The facility was built with the collaboration of public bodies, donors, missionaries and doctors. Catholic Health Australia, ...
10 in caring for patients with ear, nose and throat (ENT) conditions and No. 16 in cancer care, according to the 2019-20 U.S. ... The 243-bed system delivers a broad range of health care services, technology and facilities. With 2,700 team members and over ... UM Shore Regional Health's key services include stroke care, breast cancer screening and treatment, and cardiovascular and ... Joseph Medical Center specializes in cancer care, cardiology, orthopaedics, women's health, children's services and emergency ...
Based in Spartanburg, Gibbs Cancer Center & Research Institute provides comprehensive cancer care to the Upstate South Carolina ... is a 125-bed acute care facility located in Gaffney, S.C., that services Cherokee County and the surrounding areas. The ... Located on Floyd Baker Boulevard, Immediate Care Center - Gaffney provides a hybrid of urgent and primary care. A network of ... "Cancer Treatment at Gibbs Cancer Center - Spartanburg Regional Healthcare System". www.spartanburgregional.com. Retrieved 2019- ...
It has two general hospitals in Kirkland and Monroe, and several smaller clinics and urgent care facilities in King and ... and has partnerships with the Seattle Cancer Care Alliance. "Discussion to Continue at Redmond of Proposed Public Hospital ... The organization was renamed in 1996 to Evergreen Healthcare Medical Group and began opening primary care facilities around the ... The King County facilities served 340,146 outpatient visits, while the Snohomish County facilities served 16,257 visits. ...
Prinsloo died on December 2, 2017, aged 79, at a Toronto palliative care facility after being diagnosed with brain cancer. ...
... a breast cancer care unit, an oncology unit and improved the imaging unit with new equipment. It claims that its diagnostic ... facilities are the most advanced available in the UK outside London. Under the new management the number of permanent staff has ... St Anne's Hospice, which has 10 beds, in the hospital grounds, was transferred to the management of St David's Hospice Care in ...
... cancer care and orthopaedics, and neurosurgery. The hospital is an acute care facility and operates the only full service ... Urban Health Scholars gain valuable exposure to the complex and challenging issues of health care in the inner city. In UST's ... Through Bioscience Connecticut, construction will begin in 2013 for a new patient care tower on the UConn Health campus, as ... Through Bioscience Connecticut, a new ambulatory care center began construction in 2012 on the UConn Health campus, part of a $ ...
At the age of 78, Rimland died of prostate cancer on November 21, 2006 at a care facility in El Cajon, California. 1964 ...
Rutledge Tower Ambulatory Care Facility renovation (1998), College of Health Professions Complex (2005), Hollings Cancer Center ... burn care, ophthalmology, hearing loss, genetics, pediatric emergency services, rheumatology, and cancer care. In 1994, Peter B ... and the Hollings Cancer Center is a National Cancer Institute distinguished cancer research center. The School of Dental ... Patient care Dental student clinics: Specialty care graduate clinics: Pediatrics, Periodontics, Orthodontics, and Oral Surgery ...
Trinity's facilities include three acute care hospitals (Trinity Hospital and Trinity Hospital-St. Joseph's in Minot and ... In January 2009, it opened its CancerCare Cottage, a building which accommodations for cancer patients and their caregivers ... and a 292-bed long-term care and retirement facility. Trinity has been designated as a Level II trauma center. During the early ... the victims of the Hepatitis C outbreak sued HCR Manor Care. In March 2015, HCR Manor Care and 21 victims sued Trinity after it ...